
In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …

Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for …

Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.How did …

Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a …

Alison Hollands, Vice President, Respiratory, UK Pharmaceuticals at GlaxoSmithKline, addresses the importance of implementing the latest approaches to treating COPD …

Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. …

Louis Goss asks what the future might hold for the safety of pharmaceuticals and looks into why crucial pharmacovigilance practices …

While immunotherapies continue to be the darling of the industry, new, innovative and sometimes seemingly fantastical research is emerging that …

Excitement is building for the potential of AI in just about every field, but how can it address pharma’s unique …

Second medical use patents protect the discovery that an existing drug is effective to treat a new condition. But, following …

Michael Connellan, Head of External Affairs at the type 1 diabetes charity JDRF, discusses the results of a recent survey …

Professor Matthew Hotopf, Director of NIHR Maudsley Biomedical Research Centre, and Professor John R Geddes, Director of NIHR Oxford Health …

With shocking new findings revealing that around half of all clinical trial results in Europe go unreported, Matt Fellows explores …

They’re two of the biggest buzzwords getting professionals excited across pharma – Anjali Shukla explores the ways in which AI …

Just as his company announced robust H1 2018 financials, UCB’s Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of …